BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-04-23 ms4000000738376966

审稿速度:1.0
偏重的研究方向：药理学;肿瘤;药理
经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险

41 0

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-04-17 ms4000000738376966

偏重的研究方向：肿瘤;药理
经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿

56 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-03-28 ms4000000738376966

偏重的研究方向：药理学;肿瘤;药理
经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变

57 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-04-15 1250d11bm60(暂无昵称)

偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述
经验分享：投稿到接收2个月

56 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-03-22 ms6000002059361445

偏重的研究方向：中药单体;肿瘤;药理
经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？

73 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-03-30 ms2000001401387191

请问这个纯生信收吗

37 0

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2020-07-18 scimonitor

投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。

115 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2022-02-05 yjq08018275

这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不

65 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2021-11-30 第五先生

偏重的研究方向：中药单体;药理;药物治疗
经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。

94 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1213552, encodeId=083312135527b, content=审稿速度:1.0 偏重的研究方向：药理学;肿瘤;药理 经验分享：我在投稿的时候忘记给作者加共一标识，目前文章在小修阶段，请问现在可以加吗，有没有什么风险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sat Apr 23 00:28:55 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212004, encodeId=08741212004d3, content=偏重的研究方向：肿瘤;药理 经验分享：请问大家，我的文章修回，怎么看需要修改分地方啊，也不知道是小修还是大修，**次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Sun Apr 17 21:52:28 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206746, encodeId=6fd71206e46ae, content=偏重的研究方向：药理学;肿瘤;药理 经验分享：为什么我的with editor到under Review 是7天，第一次under Review时间改变是7天，然后其他后时间又变了，但是状态不变 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c15690722, createdName=ms4000000738376966, createdTime=Mon Mar 28 23:29:43 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211407, encodeId=89b7121140e0e, content=偏重的研究方向：接收了1篇，今年IF预计接近8分;神经药理综述 经验分享：投稿到接收2个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Apr 15 12:05:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204972, encodeId=edd812049e2db, content=偏重的研究方向：中药单体;肿瘤;药理 经验分享：请问兄弟姐妹们，这个杂志送审后被拒的概率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039c6560249, createdName=ms6000002059361445, createdTime=Tue Mar 22 16:25:41 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207220, encodeId=94f0120e22026, content=请问这个纯生信收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7fa6150272, createdName=ms2000001401387191, createdTime=Wed Mar 30 14:56:11 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803159, encodeId=bdf480315962, content=投稿要求越来越多，例如提供原始WB图片，审核过程极其严格。杂志质量不断提高。说垃圾杂志的，也许1年前被拒过稿子吧。现在更难了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d7f1613305, createdName=scimonitor, createdTime=Sat Jul 18 00:41:59 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190416, encodeId=70e71190416cb, content=这杂志目前接受率如何啊 1月12日投稿后 with editor , 1月31日under review ，有希望不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bdb4724485, createdName=yjq08018275, createdTime=Sat Feb 05 23:19:24 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075602, encodeId=69eb10e5602fe, content=偏重的研究方向：中药单体;药理;药物治疗 经验分享：最近大家投稿速度怎么样？？我投了快一周了，咋还是submitted 。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Nov 30 22:32:08 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004826, encodeId=e65f1004826d7, content=官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34632548251, createdName=1253793fm75(暂无昵称), createdTime=Tue Aug 03 09:33:41 CST 2021, time=2021-08-03, status=1, ipAttribution=)]

2021-08-03 1253793fm75(暂无昵称)

官网说这个杂志第一次决定是2周。投这个杂志上传WB原图后第三天说文章在editor-in-chief那里，过了10天状态依然是with editor，我可以催一下编辑不，大家有什么经验！多谢，急着毕业！！！

115 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务